HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROMES
DOI:
https://doi.org/10.46765/2675-374X.2023v4n1p178Keywords:
Consensus, Update, Myelodysplastic DiseaseAbstract
The document discuss key points in the management of patients with Myelodysplastic Disease, including therapeutic strategies, the role of new drugs available as well the Hematopoietic Stem Cell Transplantation. Other issues evaluated were importance of molecular alterations since diagnosis to prognosis, use of comprehensive geriatric assessment for patient's selection, individualization of treatment, donor selection for HSCT and the role of blasts % and molecular mutations for the appropriate diagnosis.
Downloads
Published
02/28/2023
How to Cite
Duarte, F. B. ., Karine Sampaio Nunes Barroso, Roberto Luiz da Silva, Lívia Andrade Gurgel, João Paulo de Vasconcelos Leitão, Beatriz Stela Gomes de Souza Pitombeira, … Gustavo Betarello. (2023). HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROMES. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(1), 178. https://doi.org/10.46765/2675-374X.2023v4n1p178
Issue
Section
Original article
License
Copyright (c) 2023 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





